Wellington Management Group LLP 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-12 10:44 am Sale | 2025-03-31 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 8,354,151 12.600% | -889,448 (-9.62%) | Filing |
| 2024-11-08 10:52 am Purchase | 2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 9,243,599 13.940% | 2,767,038 (+42.72%) | Filing |
| 2024-02-08 10:11 am Purchase | 2023-12-29 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 6,476,561 11.840% | 1,695,064 (+35.45%) | Filing |
| 2023-05-10 08:54 am Purchase | 2023-04-28 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 4,781,497 10.120% | 133,585 (+2.87%) | Filing |
| 2023-02-06 2:49 pm Purchase | 2022-12-30 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 4,647,912 9.870% | 4,647,912 (New Position) | Filing |